Mon.Mar 25, 2024

article thumbnail

FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

Bio Pharma Dive

The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.

Antibody 299
article thumbnail

Cancer Research UK and CRIS fund lung cancer vaccine research

Pharmaceutical Technology

Cancer Research UK and the CRIS Cancer Foundation have awarded a £1.7m ($2.1m) grant for developing the lung cancer vaccine LungVax.

Vaccine 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Axsome drug succeeds in narcolepsy symptoms trial

Bio Pharma Dive

Despite the late-stage victory, shares of the New York-based biotech dipped more than 3%. One analyst argued that Axsome’s drug has “largely been falling under investor radars.

Drugs 182
article thumbnail

FDA approves J&J’s OPSYNVI for pulmonary arterial hypertension

Pharmaceutical Technology

The US FDA approved Johnson & Johnson's (J&J) OPSYNVI for chronic treatment in adult patients with pulmonary arterial hypertension.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

AbbVie to buy immune drug developer Landos

Bio Pharma Dive

Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

Drugs 173
article thumbnail

Elahere secures full approval from FDA for types of ovarian cancer

Pharmaceutical Technology

The FDA granted accelerated approval for the drug back in November 2022, and granted priority review in December 2023.

Drugs 246

More Trending

article thumbnail

March 25, 2024: PCORI Announces Foundational Expectations for Partnerships in Research

Rethinking Clinical Trials

The Patient-Centered Outcomes Research Institute (PCORI) announced the release of its new Foundational Expectations for Partnerships in Research. The resource is an update of the 2014 PCORI Engagement Rubric. It builds on a growing body of evidence about engaging patients and other partners in patient-centered comparative effectiveness research. A webinar on April 4 will explore the foundational expectations, which PCORI describes as “building blocks for meaningful, effective, and sustaina

Research 150
article thumbnail

The future of companion diagnostic (CDx) development: Why commercialization is key

Bio Pharma Dive

As precision medicine expands into a growing number of therapeutic areas, the “one size fits all” approach to drug development is becoming less common.

article thumbnail

CRISPR-based assay could revolutionise diagnosis of NTM infections

Pharmaceutical Technology

The CRISPR-based assay significantly accelerates the current diagnostic process, which can last for months and could revolutionise the way NTM infections are diagnosed.

147
147
article thumbnail

Improving clinical trial design with real-world data

Bio Pharma Dive

Leveraging real-world data (RWD) transforms global clinical trials, enhancing patient engagement and improving regulatory decision-making.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

BioNTech Hit with NIH Notice of Default over COVID-19 Vaccine Royalties

BioSpace

The National Institutes of Health claims BioNTech is in default regarding alleged royalty payments the agency contends it is owed in connection with the company’s COVID-19 vaccine Comirnaty.

Vaccine 145
article thumbnail

In banner year, Lilly rewards CEO David Ricks with 24% boost in total pay to $26.6M

Fierce Pharma

In 2023, Eli Lilly CEO David Ricks received a 24% boost in pay from $21.4 million to $26.6 million. The increase coincides with the company's booming sales.

Sales 143
article thumbnail

Novo shells out $1.1bn to buy Cardior to expand cardiovascular pipeline

Pharmaceutical Technology

Novo Nordisk will pay up to $1.1bn in upfront and milestone-based payments, with the acquisition expected to close in Q2 2024.

130
130
article thumbnail

BioNTech hit with 'notice of default' from NIH in COVID-19 vaccine royalty dispute

Fierce Pharma

Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S. | Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S. officials are pressing the company to pay royalties linked to the commercialization of its lucrative Pfizer-partnered COVID-19 vaccine.

Vaccine 141
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Pharmaceutical packaging companies and labelling machines

Pharmaceutical Technology

Download our extensive, free list of the leading pharmaceutical packaging companies and labelling machine manufacturers today.

Packaging 130
article thumbnail

With Merck's key PAH approval on tap, Johnson & Johnson wins nod for combo tablet

Fierce Pharma

With the FDA expected this week to approve a first-in-class treatment from Merck for pulmonary arterial hypertension (PAH), Johnson & Johnson has beaten its New Jersey rival to the punch with a | With the FDA expected this week to approve a first-in-class treatment from Merck for pulmonary arterial hypertension (PAH), Johnson & Johnson has beaten its New Jersey rival to the punch with a nod from the U.S. regulator for its newest PAH treatment.

article thumbnail

Esperion snags US label expansion for cardiovascular disease drugs

Pharmaceutical Technology

Esperion Therapeutics’ Nexletol and Nexlizet are now available for patients with cardiovascular risk in the US.

Drugs 130
article thumbnail

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

pharmaphorum

Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.1 billion, adding expertise in RNA therapeutics and a heart failure therapy in mid-stage trials.

RNA 122
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Gilead acquires CymaBay Therapeutics for $4.3bn

Pharmaceutical Technology

Gilead Sciences has concluded the acquisition of CymaBay Therapeutics in a transaction valued at approximately $4.3bn.

130
130
article thumbnail

AstraZeneca’s rare disease unit overcomes FDA snub to expand Ultomiris in NMOSD

Fierce Pharma

Nearly five years after an FDA approval for Soliris in neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s follow-on C5 drug Ultomiris has entered the rare neurological disease, as well.< | Nearly five years after an FDA approval for Soliris in neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s follow-on C5 drug Ultomiris has entered the rare neurological disease, as well.

article thumbnail

Birmingham University to develop lollipop for mouth cancer detection

Pharmaceutical Technology

The University of Birmingham has secured £350,000 in funding to develop a flavoured "lollipop" for the early detection of mouth cancer.

article thumbnail

Invivyd's COVID prophylactic scores FDA emergency nod for people with weakened immune systems

Fierce Pharma

The four years since the start of the COVID-19 pandemic have yielded many advances against the coronavirus, including Moderna and Pfizer’s groundbreaking mRNA vaccines. | The agency granted emergency use authorization to Invivyd's Pemgarda, a monoclonal antibody for those who are immunocompromised and unlikely to receive adequate protection from marketed mRNA vaccines.

Antibody 116
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

AriBio licenses Alzheimer’s pill in China for up to $770m

Pharmaceutical Technology

An unnamed Chinese partner takes on AR1001 in an APAC Alzheimer’s market predicted to be worth $2.

Licensing 130
article thumbnail

FTC weighs in on Teva's inhaler litigation against Amneal amid far-reaching patent crackdown

Fierce Pharma

When it comes to questioning drug patents, the U.S. Federal Trade Commission (FTC) isn’t backing down. | After filing a challenge in November against more than 100 patents in the FDA’s Orange Book—and persuading several drugmakers to retract their intellectual property (IP) protections in the process—the U.S. Federal Trade Commission is now calling out uncooperative companies in court.

Drugs 115
article thumbnail

NICE endorses use of digital therapies for psychosis

pharmaphorum

Three digital health technologies (DHTs) used to support patients with psychosis can be used by the NHS while additional evidence of their benefits is gathered.

115
115
article thumbnail

New wave of potential therapies to bring ‘paradigm shift’ in COPD treatment

BioPharma Reporter

The recent submission of clinical trial data for Sanofi/Regeneronâs Dupixent and Veronaâs Ensifentrine to the U.S. FDA indicates the entry of new therapies for chronic obstructive pulmonary disease (COPD) in 2024.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

FDA turns down Regeneron bispecific blood cancer antibody

pharmaphorum

FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma

Antibody 111
article thumbnail

Chocolate Shortage Looms Ahead of Easter 2024

XTalks

As Easter 2024 approaches, a concerning chocolate shortage threatens to cast a shadow over the season’s celebrations. This shortage, attributed to a combination of factors including poor cocoa harvests in West Africa, is poised to impact chocolate lovers worldwide. The Root of the Chocolate Shortage For the past three years, the cocoa industry has grappled with underwhelming harvests, significantly driving up prices.

article thumbnail

Skin biopsy test detects abnormalities of key biomarker in neurodegenerative disorders

Pharma Times

Estimated to affect 2.

110
110
article thumbnail

Oprah Hosts TV Special About GLP-1 Drugs for Weight Loss

XTalks

After more than a decade, Oprah Winfrey returned to prime-time TV last week for an ABC special titled “Shame, Blame and the Weight Loss Revolution” to share her public battle with weight and her decision to use new GLP-1 medications to help manage it. In the hour-long TV special that Oprah hosted, set on a stage reminiscent of her iconic talk show, the talk show icon said, “I took on the shame that the world gave to me.

Drugs 105
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.